HOME HELP FEEDBACK ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Jantunen, E. PubMed PubMed Citation Articles by Jantunen, E.

Autologous stem cell transplantation in elderly patients ( 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

¹ Department of Medicine, Kuopio University Hospital, Kuopio, Finland
² Banc de Sang i Teixits, Barcelona, Spain
³ Divisione di Ematologia, Ospedale Bergamo, Bergamo, Italy
⁴ Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
⁵ Hematology Department, H SS. Antonio e Biagio, Alessandria, Italy
⁶ Unitè de transplantation et de therapie cellulaire, Institut Paoli Calmettes, Marseille, France
⁷ Servicio de Hematologia-Hemoterapia, Hospital U. Marques de Valdecilla, Santander, Spain
⁸ Hematology, Centre Henri Becquerel, Rouen, France
⁹ Blood and Bone Marrow Transplant Centre, St. James’ University Hospital, Leeds, United Kingdom
¹⁰ Centre for Clinical Haematology, Birmingham, United Kingdom
¹¹ Division of Hematology, Az. Ospedaliera S. Croce e Carle, Cuneo, Italy
¹² Nottingham City Hospital, Nottingham, United Kingdom
¹³ Service d’Onco-Hématologie, Hopital l'Archet, Nice, France
¹⁴ Medizinische Klinik, University of Heidelberg, Heidelberg, Germany
¹⁵ Internal Medicine, University of Saarland, Homburg, Germany
¹⁶ Clinical Hematology Division, Hospital Santa Creu i Sant Pau, Barcelona, Spain

Correspondence: Esa Jantunen, MD, PhD, Department of Medicine, Kuopio University Hospital, P.O.B. 1777, 70211 Kuopio, Finland. E-mail:esa.jantunen{at}kuh.fi

ABSTRACT

Background: There is currently limited experience on the feasibility and efficacy of autologous stem cell transplantation in elderly patients with diffuse large B-cell lymphoma.

Design and Methods: We analyzed the outcome of 2612 patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation between 2000 and 2005 and reported to the European Blood and Marrow Transplantation registry. Four hundred and sixty-three patients (18%) were 60 years old at the time of the transplant (median, 63 years). When compared to 2149 patients <60 years old at the time of transplantation, the elderly patients had more frequently received at least two treatment lines (76% vs. 57%, p<0.001), were less commonly in first complete remission at the time of transplantation (23 % vs. 30 %, p=0.005) and received their transplants later after diagnosis (median time 14 months vs.7.5 months, p<0.001).

Results: Non-relapse mortality was higher in elderly patients at 100 days (4.4 % vs. 2.8 %), at 1 year (8.7% vs. 4.7%) and at 3 years (10.8% vs. 6.5%) (p=0.002). With a median follow-up of 12 months for the surviving patients for the elderly group and 15 months for the younger group, the risk of relapse was 38% and 32%, respectively (p=0.006).The progression-free survival was 51% and 62%, respectively, at 3 years (p<0.001). The overall survival rate was 60% vs. 70%, respectively, at 3 years (p<0.001).

Conclusions: Autologous stem cell transplantation is feasible in selected elderly patients with diffuse large B-cell lymphoma, although non-relapse mortality is somewhat higher than in younger patients. Both progression-free and overall survival rates are promising taking into account the generally poorer outcome of elderly patients with diffuse large B-cell lymphoma.

Key words: autologous stem cell transplantation, diffuse large B-cell lymphoma, elderly patients, non-relapse mortality, outcome.